Staphylococcus aureus bacteraemia (SAB) is a clinically heterogeneous disease. The ability to identify sub-groups of patients with shared traits (subphenotypes) is an unmet need to allow patient stratification for clinical management and research. We have reproducibly identified distinct SAB subphenotypes using routinely collected clinical data (Swets et al, Clin Infect Dis 2024;79:1153-61):
(A) SAB associated with older age and comorbidity
(B) nosocomial intravenouscatheter-associated SAB in younger people without comorbidity
(C)community-acquired metastatic SAB
(D) SAB associated with chronic kidneydisease and haemodialysis
(E) SAB associated with injection drug use.
The SNAPstrat sub-study will determine if these subphenotypes can be identified amongst patients included in the trial, then determine if differential treatment effects exist for the trial interventions when patients are stratified by subphenotype membership.
SNAP Trial
Cefazolin Versus Penicillin for Penicillin-Susceptible Staphylococcus aureus Bacteremia: A Secondary Analysis of the SNAP Backbone Trials
Significance of S. aureus bacteriuria in patients hospitalized with S. aureus bacteremia
A statistical genomics framework to improve prediction of treatment outcomes of Staphylococcus aureus bacteraemia (SAB)
